M
ME NEWS
16 Jun 2025, 14:47
TG Therapeutics Shareholders Approve All 2025 Annual Meeting Proposals
TG Therapeutics, Inc. conducted its 2025 Annual Meeting of Stockholders on June 12 via an online platform, with 74.58% of outstanding shares represented. All four proposals on the ballot received shareholder approval.
Six directors, including CEO Michael S. Weiss, were re-elected, though some—such as Dr. Sagar Lonial and Yann Echelard—faced notable opposition, receiving around 54% and 59% of votes in favor, respectively.
Shareholders also ratified KPMG LLP as the company’s auditor for 2025 and approved the executive compensation plan in a close advisory vote. Additionally, they approved an amendment to the 2022 Incentive Plan, increasing the authorized share count from 17 million to 22 million.
TG Therapeutics, Inc. conducted its 2025 Annual Meeting of Stockholders on June 12 via an online platform, with 74.58% of outstanding shares represented. All four proposals on the ballot received shareholder approval.
Six directors, including CEO Michael S. Weiss, were re-elected, though some—such as Dr. Sagar Lonial and Yann Echelard—faced notable opposition, receiving around 54% and 59% of votes in favor, respectively.
Shareholders also ratified KPMG LLP as the company’s auditor for 2025 and approved the executive compensation plan in a close advisory vote. Additionally, they approved an amendment to the 2022 Incentive Plan, increasing the authorized share count from 17 million to 22 million.